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1497PreambleThe medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the beneﬁts and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to
a thorough review of evidence has resulted in the production
of clinical practice guidelines that assist clinicians in selecting
the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a founda-
tion for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
produced guidelines in the area of cardiovascular disease
since 1980. The ACCF/AHA Task Force on Practice Guide-
lines (Task Force), charged with developing, updating, and
revising practice guidelines for cardiovascular diseases and
procedures, directs and oversees this effort. Writing
committees are charged with regularly reviewing and evalu-
ating all available evidence to develop balanced, patient-
centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-speciﬁc data and write
guidelines in partnership with representatives from other
medical organizations and specialty groups. Writing commit-
tees are asked to perform a literature review; weigh the
strength of evidence for or against particular tests, treatments,
or procedures; and include estimates of expected outcomes
where such data exist. Patient-speciﬁc modiﬁers, comorbid-
ities, and issues of patient preference that may inﬂuence the
choice of tests or therapies are considered. When available,
information from studies on cost is considered, but data on
efﬁcacy and outcomes constitute the primary basis for the
recommendations contained herein.
In analyzing the data and developing recommendations and
supporting text, the writing committee uses evidence-based
methodologies developed by the Task Force (1). The Class
of Recommendation (COR) is an estimate of the size of the
treatment effect considering risks versus beneﬁts in addition
to evidence and/or agreement that a given treatment or
procedure is or is not useful/effective or in some situations
may cause harm. The Level of Evidence (LOE) is an
estimate of the certainty or precision of the treatment effect.
The writing committee reviews and ranks evidence
supporting each recommendation with the weight of evidence
ranked as LOE A, B, or C according to speciﬁc deﬁnitions
that are included in Table 1. Studies are identiﬁed as
observational, retrospective, prospective, or randomized
where appropriate. For certain conditions for which
inadequate data are available, recommendations are based onexpert consensus and clinical experience and are ranked as
LOE C. When recommendations at LOE C are supported by
historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues for which
sparse data are available, a survey of current practice among
the clinicians on the writing committee is the basis for LOE C
recommendations and no references are cited. The schema for
COR and LOE are summarized in Table 1, which also
provides suggested phrases for writing recommendations
within each COR. A new addition to this methodology is
separation of the Class III recommendations to delineate
whether the recommendation is determined to be of “no
beneﬁt” or is associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested
phrases for writing recommendations for the comparative
effectiveness of one treatment or strategy versus another have
been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as deﬁned by
ACCF/AHA guidelinerecommended therapies (primarily
Class I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and clinicians) residing in North Amer-
ica, drugs that are not currently available in North America
are discussed in the text without a speciﬁc COR. For studies
performed in large numbers of subjects outside North
America, each writing committee reviews the potential
inﬂuence of different practice patterns and patient populations
on the treatment effect and relevance to the ACCF/AHA
target population to determine whether the ﬁndings should
inform a speciﬁc recommendation.
The ACCF/AHA practice guidelines are intended to assist
clinicians in clinical decision making by describing a range
of generally acceptable approaches to the diagnosis,
management, and prevention of speciﬁc diseases or condi-
tions. The guidelines attempt to deﬁne practices that meet
the needs of most patients in most circumstances. The
ultimate judgment regarding care of a particular patient must
be made by the clinician and patient in light of all the
circumstances presented by that patient. As a result, situa-
tions may arise for which deviations from these guidelines
may be appropriate. Clinical decision making should
involve consideration of the quality and availability of
expertise in the area where care is provided. When these
guidelines are used as the basis for regulatory or payer
decisions, the goal should be improvement in quality of
care. The Task Force recognizes that situations arise in
which additional data are needed to inform patient care more
effectively; these areas will be identiﬁed within each
respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
Table 1. Applying Classification of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do
not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful
or effective.
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use.
yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve
direct comparisons of the treatments or strategies being evaluated.
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1498of patient understanding and adherence may adversely affect
outcomes, clinicians should make every effort to engage the
patient’s active participation in prescribed medical regimens
and lifestyles. In addition, patients should be informed of the
risks, beneﬁts, and alternatives to a particular treatment and
be involved in shared decision making whenever feasible,
particularly for COR IIa and IIb, for which the beneﬁt-to-risk
ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may arise asa result of industry relationships or personal interests among
the members of the writing committee. All writing committee
members and peer reviewers of the guideline are required to
disclose all current healthcare-related relationships, including
those existing 12 months before initiation of the writing effort.
In December 2009, the ACCF and AHA implemented a new
policy for relationship with industry and other entities (RWI)
that requires the writing committee chair plus a minimum
of 50% of the writing committee to have no relevant
RWI (Appendix 1 includes the ACCF/AHA deﬁnition of
JACC Vol. 62, No. 16, 2013 Yancy et al.
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1499relevance). These statements are reviewed by the Task Force
and all members during each conference call and/or meeting
of the writing committee and are updated as changes occur.
All guideline recommendations require a conﬁdential vote
by the writing committee and must be approved by
a consensus of the voting members. Members are not
permitted to draft or vote on any text or recommendations
pertaining to their RWI. Members who recused themselves
from voting are indicated in the list of writing committee
members, and speciﬁc section recusals are noted in
Appendix 1. Authors’ and peer reviewers’ RWI pertinent to
this guideline are disclosed in Appendixes 1 and 2,
respectively. Additionally, to ensure complete transparency,
writing committee members’ comprehensive disclosure
informationdincluding RWI not pertinent to this
documentdis available as an online supplement.
Comprehensive disclosure information for the Task Force is
also available online at http://www.cardiosource.org/en/
ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-
Documents-Task-Forces.aspx. The work of writing
committees is supported exclusively by the ACCF and
AHA without commercial support. Writing committee
members volunteered their time for this activity.
In an effort to maintain relevance at the point of care for
practicing clinicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to these guidelines
will be apparent, including limited narrative text, a focus on
summary and evidence tables (with references linked to
abstracts in PubMed), and more liberal use of summary
recommendation tables (with references that support LOE) to
serve as a quick reference.
In April 2011, the Institute of Medicine released 2 reports:
Clinical Practice Guidelines We Can Trust and Finding What
Works in Health Care: Standards for Systematic Reviews
(2,3). It is noteworthy that the ACCF/AHA practice guide-
lines are cited as being compliant with many of the proposed
standards. A thorough review of these reports and of our
current methodology is under way, with further enhancements
anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update or the
full-text guideline is revised. Guidelines are ofﬁcial policy of
both the ACCF and AHA. The reader is encouraged to consult
the full-text guideline (4). for additional guidance and details
about heart failure, because the Executive Summary contains
only the recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever
possible, evidence based. An extensive evidence review wasconducted through October 2011 and includes selected other
references through April 2013. The relevant data are included
in evidence tables in the Data Supplement. Searches were
extended to studies, reviews, and other evidence conducted in
human subjects and that were published in English from
PubMed, EMBASE, Cochrane, Agency for Healthcare
Research and Quality Reports, and other selected databases
relevant to this guideline. Key search words included but were
not limited to the following: heart failure, cardiomyopathy,
quality of life, mortality, hospitalizations, prevention,
biomarkers, hypertension, dyslipidemia, imaging, cardiac
catheterization, endomyocardial biopsy, angiotensin-
converting enzyme inhibitors, angiotensin-receptor antago-
nists/blockers, beta blockers, cardiac, cardiac resynchroni-
zation therapy, deﬁbrillator, device-based therapy,
implantable cardioverter-deﬁbrillator, device implantation,
medical therapy, acute decompensated heart failure,
preserved ejection fraction, terminal care and trans-
plantation, quality measures, and performance measures.
Additionally, the committee reviewed documents related to
the subject matter previously published by the ACCF and
AHA. References selected and published in this document are
representative and not all-inclusive.
1.2. Organization of the Writing Committee
The committee was composed of physicians and a nurse with
broad expertise in the evaluation, care, and management of
patients with heart failure (HF). The authors included general
cardiologists, HF and transplant specialists, electrophysiolo-
gists, general internists, and physicians with methodological
expertise. The committee included representatives from the
ACCF, AHA, American Academy of Family Physicians,
American College of Chest Physicians, American College of
Physicians, Heart Rhythm Society, and International Society
for Heart and Lung Transplantation.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by both the ACCF and the AHA, as well as 1 to 2
reviewers each from the American Academy of Family
Physicians, American College of Chest Physicians, Heart
Rhythm Society, and International Society for Heart and Lung
Transplantation, as well as 32 individual content reviewers
(including members of the ACCF Adult Congenital and Pedi-
atric Cardiology Council, ACCF Cardiovascular Team Council,
ACCF Council on Cardiovascular Care for Older Adults,
ACCF Electrophysiology Committee, ACCF Heart Failure and
Transplant Council, ACCF Imaging Council, ACCF Prevention
Committee, ACCF Surgeons’ Scientiﬁc Council, and ACCF
Task Force on Appropriate Use Criteria). All information on
reviewers’ RWI was distributed to the writing committee and is
published in this document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and AHA and endorsed by the
American Association of Cardiovascular and Pulmonary
Rehabilitation, American College of Chest Physicians, Heart
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1500Rhythm Society, and International Society for Heart and Lung
Transplantation.1.4. Scope of This Guideline With Reference
to Other Relevant Guidelines or Statements
This guideline covers multiple management issues for the
adult patient with HF. Although there is an abundance of
evidence addressing HF, for many important clinical consid-
erations, this writing committee was unable to identify sufﬁ-
cient data to properly inform a recommendation. The writing
committee actively worked to reduce the number of LOE “C”
recommendations, especially for Class Irecommended
therapies. Despite these limitations, it is apparent that much
can be done for HF. Adherence to the clinical practice
guidelines herein reproduced should lead to improved patient
outcomes.
Although of increasing importance, children with HF and
adults with congenital heart lesions are not speciﬁcally
addressed in this guideline. The reader is referred to publi-
cally available resources to address questions in these areas.
However, this guideline does address HF with preserved
ejection fraction (EF) in more detail and similarly revisits
hospitalized HF. Additional areas of renewed interest are
stage D HF, palliative care, transition of care, and quality of
care for HF. Certain management strategies appropriate for
the patient at risk for HF or already affected by HF are also
reviewed in numerous relevant clinical practice guidelines
and scientiﬁc statements published by the ACCF/AHA Task
Force on Practice Guidelines, AHA, ACCF Task Force on
Appropriate Use Criteria, European Society of Cardiology,
Heart Failure Society of America, and the National Heart,
Lung, and Blood Institute. The writing committee saw no
need to reiterate the recommendations contained in those
guidelines and chose to harmonize recommendations when
appropriate and eliminate discrepancies. This is especially the
case for device-based therapeutics, where complete align-
ment between the HF guideline and the device-based
therapy guideline was deemed imperative (5). Some
recommendations from earlier guidelines have been updated
as warranted by new evidence or a better understanding of
earlier evidence, whereas others that were no longer
accurate or relevant or that were overlapping were
modiﬁed; recommendations from previous guidelines that
were similar or redundant were eliminated or consolidated
when possible.
The present document recommends a combination of life-
style modiﬁcations and medications that constitute GDMT.
GDMT is speciﬁcally referenced in the recommendations for
treatment of HF (Section 6.3.2). Both for GDMT and other
recommended drug treatment regimens, the reader is advised
to conﬁrm dosages with product insert material and to
evaluate carefully for contraindications and drug-drug
interactions. Table 2 is a list of documents deemed pertinent
to this effort and is intended for use as a resource; it obviates
the need to repeat already extant guideline recommendations.Additional other HF guideline statements are highlighted as
well for the purpose of comparison and completeness.2. Deﬁnition of HF
HF is a complex clinical syndrome that results from any
structural or functional impairment of ventricular ﬁlling or
ejection of blood. The cardinal manifestations of HF are
dyspnea and fatigue, which may limit exercise tolerance, and
ﬂuid retention, which may lead to pulmonary and/or
splanchnic congestion and/or peripheral edema. Some patients
have exercise intolerance but little evidence of ﬂuid retention,
whereas others complain primarily of edema, dyspnea, or
fatigue. Because some patients present without signs or
symptoms of volume overload, the term “heart failure” is
preferred over “congestive heart failure.” There is no single
diagnostic test for HF because it is largely a clinical diagnosis
based on a careful history and physical examination.
The clinical syndrome of HF may result from disorders of
the pericardium, myocardium, endocardium, heart valves, or
great vessels, or from certain metabolic abnormalities, but
most patients with HF have symptoms due to impaired left
ventricular (LV) myocardial function. It should be empha-
sized that HF is not synonymous with either cardiomyopathy
or LV dysfunction; these latter terms describe possible
structural or functional reasons for the development of HF.
HF may be associated with a wide spectrum of LV functional
abnormalities, which may range from patients with normal
LV size and preserved EF to those with severe dilatation and/
or markedly reduced EF. In most patients, abnormalities of
systolic and diastolic dysfunction coexist, irrespective of EF.
EF is considered important in classiﬁcation of patients with
HF because of differing patient demographics, comorbid
conditions, prognosis, and response to therapies (36) and
because most clinical trials selected patients based on EF.
EF values are dependent on the imaging technique used,
method of analysis, and operator. As other techniques may
indicate abnormalities in systolic function among patients
with a preserved EF, it is preferable to use the terms
preserved or reduced EF over preserved or reduced systolic
function. For the remainder of this guideline, we will
consistently refer to HF with preserved EF and HF with
reduced EF as HFpEF and HFrEF, respectively (Table 3).3. HF Classiﬁcations
Both the ACCF/AHA stages of HF (37) and the New York
Heart Association (NYHA) functional classiﬁcation (37,38)
provide useful and complementary information about the
presence and severity of HF. The ACCF/AHA stages of HF
emphasize the development and progression of disease and
can be used to describe individuals and populations,
whereas the NYHA classes focus on exercise capacity and
the symptomatic status of the disease (Table 4).
Table 2. Associated Guidelines and Statements
Title Organization
Publication Year
(Reference)
Guidelines
Guidelines for the Management of Adults With Congenital Heart Disease ACCF/AHA 2008 (6)
Guidelines for the Management of Patients With Atrial Fibrillation ACCF/AHA/HRS 2011 (7–9)
Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults ACCF/AHA 2010 (10)
Guideline for Coronary Artery Bypass Graft Surgery ACCF/AHA 2011 (11)
Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities ACCF/AHA/HRS 2013 (5)
Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy ACCF/AHA 2011 (12)
Guideline for Percutaneous Coronary Intervention ACCF/AHA/SCAI 2011 (13)
Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and
Other Atherosclerotic Vascular Disease: 2011 Update
AHA/ACCF 2011 (14)
Guideline for the Diagnosis and Management of Patients With Stable Ischemic
Heart Disease
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 2012 (15)
Guideline for the Management of ST-Elevation Myocardial Infarction ACCF/AHA 2013 (16)
Guidelines for the Management of Patients With Unstable Angina/
Non–ST-Elevation Myocardial Infarction
ACCF/AHA 2013 (17)
Guidelines for the Management of Patients With Valvular Heart Disease ACCF/AHA 2008 (18)
Comprehensive Heart Failure Practice Guideline HFSA 2010 (19)
Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure ESC 2012 (20)
Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary
and Secondary Care
NICE 2010 (21)
Antithrombotic Therapy and Prevention of Thrombosis ACCP 2012 (22)
Guidelines for the Care of Heart Transplant Recipients ISHLT 2010 (23)
Statements
Contemporary Definitions and Classification of the Cardiomyopathies AHA 2006 (24)
Genetics and Cardiovascular Disease AHA 2012 (25)
Appropriate Utilization of Cardiovascular Imaging in Heart Failure ACCF 2013 (26)
Appropriate Use Criteria for Coronary Revascularization Focused Update ACCF 2012 (27)
Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure
NHLBI 2003 (28)
Implications of Recent Clinical Trials for the National Cholesterol Education
Program Adult Treatment Panel III Guidelines
NHLBI 2002 (29)
Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention
Programs at Clinical Centers and Beyond
AHA/AACVPR 2011 (30)
Decision Making in Advanced Heart Failure AHA 2012 (31)
Recommendations for the Use of Mechanical Circulatory Support: Device
Strategies and Patient Selection
AHA 2012 (32)
Advanced Chronic Heart Failure ESC 2007 (33)
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial
Fibrillation
AHA/ASA 2012 (34)
Third Universal Definition of Myocardial Infarction ESC/ACCF/AHA/WHF 2012 (35)
AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AATS, American Association for Thoracic Surgery; ACCF, American College
of Cardiology Foundation; ACCP, American College of Chest Physicians; ACP, American College of Physicians; AHA, American Heart Association; ASA, American Stroke
Association; ESC, European Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; ISHLT, International Society for Heart and Lung
Transplantation; NHLBI, National Heart, Lung, and Blood Institute; NICE, National Institute for Health and Clinical Excellence; PCNA, Preventive Cardiovascular Nurses
Association; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; and WHF, World Heart Federation.
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15014. Epidemiology
The lifetime risk of developing HF is 20% for
Americans 40 years of age (39). In the United States, HF
incidence has largely remained stable over the past severaldecades, with >650 ,000 new HF cases diagnosed annually
(40–42). HF incidence increases with age, rising from
approximately 20 per 1,000 individuals 65 to 69 years of
age to >80 per 1,000 individuals among those 85 years
of age (41). Approximately 5.1 million persons in the
United States have clinically manifest HF, and the
Table 3. Definitions of HFrEF and HFpEF
Classification EF (%) Description
I. Heart failure with reduced ejection fraction (HFrEF) 40 Also referred to as systolic HF. Randomized controlled trials have mainly enrolled
patients with HFrEF, and it is only in these patients that efficacious therapies
have been demonstrated to date.
II. Heart failure with preserved ejection fraction (HFpEF) 50 Also referred to as diastolic HF. Several different criteria have been used to
further define HFpEF. The diagnosis of HFpEF is challenging because it is
largely one of excluding other potential noncardiac causes of symptoms
suggestive of HF. To date, efficacious therapies have not been identified.
a. HFpEF, borderline 41 to 49 These patients fall into a borderline or intermediate group. Their characteristics,
treatment patterns, and outcomes appear similar to those of patients with
HFpEF.
b. HFpEF, improved >40 It has been recognized that a subset of patients with HFpEF previously had HFrEF.
These patients with improvement or recovery in EF may be clinically distinct
from those with persistently preserved or reduced EF. Further research is
needed to better characterize these patients.
EF indicates ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.
Yancy et al. JACC Vol. 62, No. 16, 2013
2013 ACCF/AHA Heart Failure Guidelines: Executive Summary October 15, 2013:1495–539
1502prevalence continues to rise (40). In the Medicare-eligible
population, HF prevalence increased from 90 to 121 per
1000 beneﬁciaries from 1994 to 2003 (41). HFrEF and
HFpEF each make up about half of the overall HF burden
(43). One in 5 Americans will be >65 years of age by 2050
(44). Because HF prevalence is highest in this group, the
number of Americans with HF is expected to signiﬁcantly
worsen in the future. Disparities in the epidemiology of HF
have been identiﬁed. Blacks have the highest risk for HF
(45). In the ARIC (Atherosclerosis Risk in Communities)
study, incidence rate per 1,000 person-years was lowest
among white women, (41,42) and highest among black
men, (46) with blacks having a greater 5-year mortality rate
than whites (47). HF in non-Hispanic black males and
females has a prevalence of 4.5% and 3.8%, respectively,
versus 2.7% and 1.8% in non-Hispanic white males and
females, respectively (40).Table 4. Comparison of ACCF/AHA Stages of HF and NYHA Functional
ACCF/AHA Stages of HF (37)
A At high risk for HF but without structural heart
disease or symptoms of HF
None
B Structural heart disease but without signs or
symptoms of HF
I
C Structural heart disease with prior or current
symptoms of HF
I
II
III
IV
D Refractory HF requiring specialized interventions IV
ACCF indicates American College of Cardiology Foundation; AHA, American Heart5. Initial and Serial Evaluation of the
HF Patient: Recommendations
5.1. Clinical Evaluation
See Table 5 for multivariable clinical risk scores.
5.1.1. History and Physical Examination
CLASS I
1. A thorough history and physical examination should be ob-
tained/performed in patients presenting with HF to identify
cardiac and noncardiac disorders or behaviors that might
cause or accelerate the development or progression of HF.
(Level of Evidence: C)
2. In patients with idiopathic dilated cardiomyopathy, a 3-
generational family history should be obtained to aid in
establishing the diagnosis of familial dilated cardiomyop-
athy. (Level of Evidence: C)Classifications
NYHA Functional Classification (38)
No limitation of physical activity. Ordinary physical activity
does not cause symptoms of HF.
No limitation of physical activity. Ordinary physical activity
does not cause symptoms of HF.
Slight limitation of physical activity. Comfortable at rest,
but ordinary physical activity results in symptoms of HF.
Marked limitation of physical activity. Comfortable at rest,
but less than ordinary activity causes symptoms of HF.
Unable to carry on any physical activity without symptoms of HF,
or symptoms of HF at rest.
Unable to carry on any physical activity without symptoms of HF,
or symptoms of HF at rest.
Association; HF, heart failure; and NYHA, New York Heart Association.
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15033. Volume status and vital signs should be assessed at each
patientencounter. This includesserial assessmentofweight, as
well asestimatesof jugular venouspressureand thepresenceof
peripheral edemaor orthopnea (48–51). (Level of Evidence: B)
5.1.2. Risk Scoring
CLASS IIa
1. Validated multivariable risk scores can be useful to estimate
subsequent risk of mortality in ambulatory or hospitalized
patients with HF (52–60). (Level of Evidence: B)
5.2. Diagnostic Tests
CLASS I
1. Initial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum electro-
lytes (including calcium and magnesium), blood urea nitrogen,
serum creatinine, glucose, fasting lipid proﬁle, liver function
tests, and thyroid-stimulating hormone. (Level of Evidence: C)
2. Serial monitoring, when indicated, should include serum
electrolytes and renal function. (Level of Evidence: C)
3. A 12-lead electrocardiogram should be performed initially on
all patients presenting with HF. (Level of Evidence: C)
CLASS IIa
1. Screening for hemochromatosisorHIV is reasonable inselected
patients who present with HF (63). (Level of Evidence: C)
2. Diagnostic tests for rheumatologic diseases, amyloidosis, or
pheochromocytoma are reasonable in patients presenting
with HF in whom there is a clinical suspicion of these
diseases. (Level of Evidence: C)
5.3. Biomarkers
See Table 6 for a summary of recommendations from this
section.Table 5. Selected Multivariable Risk Scores to Predict Outcome in HF
Risk Score
Chronic HF
All patients with chronic HF
Seattle Heart Failure Model (56) http://Seat
Heart Failure Survival Score (52) http://hand
CHARM Risk Score
CORONA Risk Score
Specific to chronic HFpEF
I-PRESERVE Score
Acutely decompensated HF
ADHERE Classification and Regression Tree (CART) Model
American Heart Association Get With The Guidelines Score (58) http://www
GetWithTheGuid
%20Page_UCM
EFFECT Risk Score (55) http://www
ESCAPE Risk Model and Discharge Score
OPTIMIZE HF Risk-Prediction Nomogram
ADHERE indicates Acute Decompensated Heart Failure National Registry; CHARM, C
CORONA, Controlled RosuvastatinMultinational Trial in Heart Failure; EFFECT, Enhanced F
Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF, heart failure; HFpE
Failure with Preserved Ejection Fraction Study; and OPTIMIZE, Organized Program to InA. Ambulatory/Outpatient
CLASS I
1. In ambulatory patients with dyspnea, measurement of B-
type natriuretic peptide (BNP) or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) is useful to support clin-
ical decision making regarding the diagnosis of HF, espe-
cially in the setting of clinical uncertainty (64–70). (Level of
Evidence: A)
2. Measurement of BNP or NT-proBNP is useful for establishing
prognosis or disease severity in chronic HF (69,71–76).
(Level of Evidence: A)
CLASS IIa
1. BNP- or NT-proBNPLguided HF therapy can be useful to
achieve optimal dosing of GDMT in select clinically euvole-
mic patients followed in a well-structured HF disease
management program (77–84). (Level of Evidence: B)
CLASS IIb
1. The usefulness of serial measurement of BNP or NT-proBNP
to reduce hospitalization or mortality in patients with HF is
not well established (77–84). (Level of Evidence: B)
2. Measurement of other clinically available tests such as
biomarkers of myocardial injury or ﬁbrosis may be consid-
ered for additive risk stratiﬁcation in patients with chronic
HF (85–91). (Level of Evidence: B)B. Hospitalized/Acute
CLASS I
1. Measurement of BNP or NT-proBNP is useful to support
clinical judgment for the diagnosis of acutely decom-
pensated HF, especially in the setting of uncertainty for the
diagnosis (92–98). (Level of Evidence: A)Reference/Link
tleHeartFailureModel.org
held.softpedia.com/get/Health/Calculator/HFSS-Calc-37354.shtml
(59)
(60)
(54)
(53)
.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/
elinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-
_306087_SubHomePage.jsp
.ccort.ca/Research/CHFRiskModel.aspx
(61)
(62)
andesartan in Heart failure-Assessment of Reduction in Mortality and morbidity;
eedback for Effective Cardiac Treatment; ESCAPE, Evaluation Study of Congestive
F, heart failure with preserved ejection fraction; I-PRESERVE, Irbesartan in Heart
itiate Lifesaving Treatment in Hospitalized Patients with Heart Failure.
Table 6. Recommendations for Biomarkers in HF
Biomarker, Application Setting COR LOE References
Natriuretic peptides
Diagnosis or exclusion of HF Ambulatory, Acute I A 64–70,92–98
Prognosis of HF Ambulatory, Acute I A 69,71–76,96,99–106
Achieve GDMT Ambulatory IIa B 77–84
Guidance for acutely decompensated
HF therapy
Acute IIb C 107,108
Biomarkers of myocardial injury
Additive risk stratification Acute, Ambulatory I A 85–88,96,101,104–115
Biomarkers of myocardial fibrosis
Additive risk stratification Ambulatory IIb B 89–91
Acute IIb A 96,101,104,106–108,110,112–115
COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence.
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15042. Measurement of BNP or NT-proBNP and/or cardiac troponin
is useful for establishing prognosis or disease severity
in acutely decompensated HF (96,99–106). (Level of
Evidence: A)
CLASS IIb
1. The usefulness of BNP- or NT-proBNPLguided therapy
for acutely decompensated HF is not well established
(107,108). (Level of Evidence: C)
2. Measurement of other clinically available tests such as
biomarkers of myocardial injury or ﬁbrosis may be consid-
ered for additive risk stratiﬁcation in patients with acutely
decompensated HF (96,101,104,105,109–115). (Level of
Evidence: A)
5.4. Noninvasive Cardiac Imaging
See Table 7 for a summary of recommendations from this
section.
CLASS I
1. Patients with suspected or new-onset HF, or those pre-
senting with acute decompensated HF, should undergo
a chest x-ray to assess heart size and pulmonary congestionTable 7. Recommendations for Noninvasive Cardiac Imaging
Recommendations
Patients with suspected, acute, or new-onset HF should undergo a chest
A 2-dimensional echocardiogram with Doppler should be performed for i
Repeat measurement of EF is useful in patients with HF who have had a
in clinical status or received treatment that might affect cardiac funct
of device therapy
Noninvasive imaging to detect myocardial ischemia and viability is reaso
Viability assessment is reasonable before revascularization in HF patients
Radionuclide ventriculography or MRI can be useful to assess LVEF and
MRI is reasonable when assessing myocardial infiltration or scar
Routine repeat measurement of LV function assessment should not be p
CAD indicates coronary artery disease; COR, Class of Recommendation
left ventricular; LVEF, left ventricular ejection fraction; and MRI, magneticand to detect alternative cardiac, pulmonary, and other
diseases that may cause or contribute to the patient’s
symptoms. (Level of Evidence: C)
2. A 2-dimensional echocardiogram with Doppler should be
performed during initial evaluation of patients presenting
with HF to assess ventricular function, size, wall thickness,
wall motion, and valve function. (Level of Evidence: C)
3. Repeat measurement of EF and measurement of the severity
of structural remodeling are useful to provide information in
patients with HF who have had a signiﬁcant change in
clinical status; who have experienced or recovered from
a clinical event; or who have received treatment, including
GDMT, that might have had a signiﬁcant effect on cardiac
function; or who may be candidates for device therapy.
(Level of Evidence: C)
CLASS IIa
1. Noninvasive imaging to detect myocardial ischemia and
viability is reasonable in patients presenting with de novo
HF, who have known coronary artery disease (CAD) and no
angina, unless the patient is not eligible for revasculariza-
tion of any kind. (Level of Evidence: C)COR LOE
x-ray I C
nitial evaluation of HF I C
significant change
ion or for consideration
I C
nable in HF and CAD IIa C
with CAD IIa B (117–121)
volume IIa C
IIa B (122–124)
erformed III: No Benefit B (125,126)
; EF, ejection fraction; HF, heart failure; LOE, Level of Evidence; LV,
resonance imaging.
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15052. Viability assessment is reasonable in select situations
when planning revascularization in HF patients with CAD
(117–121). (Level of Evidence: B)
3. Radionuclide ventriculography or magnetic resonance
imaging can be useful to assess left ventricular ejection
fraction (LVEF) and volume when echocardiography is inad-
equate. (Level of Evidence: C)
4. Magnetic resonance imaging is reasonable when assessing
myocardial inﬁltrative processes or scar burden (122–124).
(Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine repeat measurement of LV function assessment in
the absence of clinical status change or treatment inter-
ventions should not be performed (125,126). (Level of
Evidence: B)5.5. Invasive Evaluation
See Table 8 for a summary of recommendations from this
section.
CLASS I
1. Invasive hemodynamic monitoring with a pulmonary artery
catheter should be performed to guide therapy in patients
who have respiratory distress or clinical evidence of
impaired perfusion in whom the adequacy or excess of
intracardiac ﬁlling pressures cannot be determined from
clinical assessment. (Level of Evidence: C)
CLASS IIa
1. Invasive hemodynamic monitoring can be useful for carefully
selected patients with acute HF who have persistent symp-
toms despite empiric adjustment of standard therapies anda. whose ﬂuid status, perfusion, or systemic or pulmonary
vascular resistance is uncertain;
b. whose systolic pressure remains low, or is associated
with symptoms, despite initial therapy;
c. whose renal function is worsening with therapy;
d. who require parenteral vasoactive agents; or
e. who may need consideration for mechanical circulatory
support (MCS) or transplantation. (Level of Evidence: C)
2. When ischemia may be contributing to HF, coronary arteri-
ography is reasonable for patients eligible for revasculari-
zation. (Level of Evidence: C)Table 8. Recommendations for Invasive Evaluation
Recommendations
Monitoring with a pulmonary artery catheter should be performed in pati
distress or impaired systemic perfusion when clinical assessment is in
Invasive hemodynamic monitoring can be useful for carefully selected pa
with persistent symptoms and/or when hemodynamics are uncertain
When ischemia may be contributing to HF, coronary arteriography is reas
Endomyocardial biopsy can be useful in patients with HF when a specific
suspected that would influence therapy
Routine use of invasive hemodynamic monitoring is not recommended in
patients with acute HF
Endomyocardial biopsy should not be performed in the routine evaluation
COR indicates Class of Recommendation; HF, heart failure; and LOE, L3. Endomyocardial biopsy can be useful in patients presenting
with HF when a speciﬁc diagnosis is suspected that would
inﬂuence therapy. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine use of invasive hemodynamic monitoring is not
recommended in normotensive patients with acute decom-
pensated HF and congestion with symptomatic response to
diuretics and vasodilators (127). (Level of Evidence: B)
CLASS III: HARM
1. Endomyocardial biopsy should not be performed in the
routine evaluation of patients with HF. (Level of Evidence: C)6. Treatment of Stages A to D:
Recommendations
6.1. Stage A
CLASS I
1. Hypertension and lipid disorders should be controlled in
accordance with contemporary guidelines to lower the risk
of HF (28,128–132). (Level of Evidence: A)
2. Other conditions that may lead to or contribute to HF, such
as obesity, diabetes mellitus, tobacco use, and known car-
diotoxic agents, should be controlled or avoided. (Level of
Evidence: C)
6.2. Stage B
See Table 9 for a summary of recommendations from this
section.
CLASS I
1. In all patients with a recent or remote history of myocardial
infarction (MI) or acute coronary syndrome (ACS) and
reduced EF, angiotensin-converting enzyme (ACE) inhibitors
should be used to prevent symptomatic HF and reduce
mortality (133–135). In patients intolerant to ACE inhibi-
tors, angiotensin-receptor blockers (ARBs) are appropriate
unless contraindicated (132,136). (Level of Evidence: A)
2. In all patients with a recent or remote history of MI or
ACS and reduced EF, evidence-based beta blockers
should be used to reduce mortality (137–139). (Level of
Evidence: B)COR LOE
ents with respiratory
adequate
I C
tients with acute HF IIa C
onable IIa C
diagnosis is IIa C
normotensive III: No Benefit B (127)
of HF III: Harm C
evel of Evidence.
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15063. In all patients with a recent or remote history of MI or ACS,
statins should be used to prevent symptomatic HF and
cardiovascular events (140–146). (Level of Evidence: A)
4. In patients with structural cardiac abnormalities, including
LV hypertrophy, in the absence of a history of MI or ACS,
blood pressure should be controlled in accordance with
clinical practice guidelines for hypertension to prevent
symptomatic HF (28,128–131). (Level of Evidence: A)
5. ACE inhibitors should be used in all patients with a reduced
EF to prevent symptomatic HF, even if they do not have
a history of MI (135,147). (Level of Evidence: A)
6. Beta blockers should be used in all patients with a reduced
EF to prevent symptomatic HF, even if they do not have
a history of MI. (Level of Evidence: C)
CLASS IIa
1. To prevent sudden death, placement of an implantable
cardioverter-deﬁbrillator (ICD) is reasonable in patients with
asymptomatic ischemic cardiomyopathy who are at least
40 days post-MI, have an LVEF of 30% or less, are on
appropriate medical therapy, and have reasonable expecta-
tion of survival with a good functional status for more than
1 year (148). (Level of Evidence: B)
CLASS III: HARM
1. Nondihydropyridine calcium channel blockers with negative
inotropic effects may be harmful in asymptomatic patients
with low LVEF and no symptoms of HF after MI. (Level of
Evidence: C)6.3. Stage C
6.3.1. Nonpharmacological Interventions
CLASS I
1. Patients with HF should receive speciﬁc education to facil-
itate HF self-care (149–154). (Level of Evidence: B)
2. Exercise training (or regular physical activity) is recom-
mended as safe and effective for patients with HF who are
able to participate to improve functional status (155–158).
(Level of Evidence: A)Table 9. Recommendations for Treatment of Stage B HF
Recommendations
In patients with a history of MI and reduced EF, ACE inhibitors or ARBs sho
used to prevent HF
In patients with MI and reduced EF, evidence-based beta blockers should b
used to prevent HF
In patients with MI, statins should be used to prevent HF
Blood pressure should be controlled to prevent symptomatic HF
ACE inhibitors should be used in all patients with a reduced EF to prevent
Beta blockers should be used in all patients with a reduced EF to prevent
An ICD is reasonable in patients with asymptomatic ischemic cardiomyopa
who are at least 40 d post-MI, have an LVEF 30%, and on GDMT
Nondihydropyridine calcium channel blockers may be harmful in patients w
low LVEF
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor
guideline-directed medical therapy; HF, heart failure; ICD, implantable car
ejection fraction; MI, myocardial infarction; and N/A, not available.CLASS IIa
1. Sodium restriction is reasonable for patients with symp-
tomatic HF to reduce congestive symptoms. (Level of
Evidence: C)
2. Continuous positive airway pressure can be beneﬁcial to
increase LVEF and improve functional status in patients with
HF and sleep apnea (159–162). (Level of Evidence: B)
3. Cardiac rehabilitation can be useful in clinically stable
patients with HF to improve functional capacity, exercise
duration, health-related quality of life, and mortality
(155,157,158,163–166). (Level of Evidence: B)
6.3.2. Pharmacological Treatment for Stage C HFrEF
CLASS I
1. Measures listed as Class I recommendations for patients in
stages A and B are recommended where appropriate for
patients in stage C. (Levels of Evidence: A, B, and C as
appropriate)
2. GDMT as depicted in Figure 1 should be the mainstay of
pharmacological therapy for HFrEF (134,136,137,167–182).
(Level of Evidence: A)
6.3.2.1. DIURETICS
See Table 10 for oral diuretics recommended for use in the
treatment of chronic HF.
CLASS I
1. Diuretics are recommended in patients with HFrEF who have
evidence of ﬂuid retention, unless contraindicated, to
improve symptoms. (Level of Evidence: C)
6.3.2.2. ACE INHIBITORS
SeeTable 11 for drugs commonly used forHFrEF (stageCHF).
CLASS I
1. ACE inhibitors are recommended in patients with HFrEF and
current or prior symptoms, unless contraindicated, to
reduce morbidity and mortality (134,167–169). (Level of
Evidence: A)COR LOE References
uld be I A 132–136
e I B 137–139
I A 140–146
I A 28,128–131
HF I A 135,147
HF I C N/A
thy IIa B 148
ith III: Harm C N/A
blocker; COR, Class of Recommendation; EF, ejection fraction; GDMT,
dioverter-defibrillator; LOE, Level of Evidence; LVEF, left ventricular
HFrEF Stage C
NYHA Class I – IV
Treatment:
For NYHA class II-IV patients.
Provided estimated creatinine
>30 mL/min and K+ <5.0 mEq/dL
For persistently symptomatic
African Americans,
NYHA class III-IV
Class I, LOE A
ACEI or ARB AND
Beta Blocker
Class I, LOE C
Loop Diuretics
Class I, LOE A
Hydral-Nitrates
Class I, LOE A
Aldosterone
Antagonist
AddAdd Add
For all volume overload,
NYHA class II-IV patients
Figure 1. Stage C HFrEF: evidence-based, guideline-directed medical therapy. ACEI indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin-receptor blocker; HFrEF, heart failure with reduced ejection fraction; Hydral-Nitrates, hydralazine and isosorbide dinitrate;
LOE, Level of Evidence; and NYHA, New York Heart Association.
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15076.3.2.3. ANGIOTENSIN-RECEPTOR BLOCKERS
CLASS I
1. ARBs are recommended in patients with HFrEF with
current or prior symptoms who are ACE inhibitor intolerant,
unless contraindicated, to reduce morbidity and mortality
(136,170,171,189). (Level of Evidence: A)
CLASS IIa
1. ARBs are reasonable to reduce morbidity and mortality as alter-
natives to ACE inhibitors as ﬁrst-line therapy for patients with
HFrEF, especially for patients already taking ARBs for other indi-
cations, unlesscontraindicated (190–195). (Level of Evidence: A)
CLASS IIb
1. Addition of an ARB may be considered in persistently
symptomatic patients with HFrEF who are already being
treated with an ACE inhibitor and a beta blocker in whom
an aldosterone antagonist is not indicated or tolerated
(176,196). (Level of Evidence: A)
CLASS III: HARM
1. Routine combined use of an ACE inhibitor, ARB, and aldo-
sterone antagonist is potentially harmful for patients with
HFrEF. (Level of Evidence: C)
6.3.2.4. BETA BLOCKERS
CLASS I
1. Use of 1 of the 3 beta blockers proven to reducemortality (e.g.,
bisoprolol, carvedilol, and sustained-release metoprolol succi-
nate) is recommended for all patients with current or prior
symptomsofHFrEF,unlesscontraindicated, to reducemorbidity
and mortality (137,172–175,187). (Level of Evidence: A)6.3.2.5. ALDOSTERONE RECEPTOR ANTAGONISTS
See Table 12 for aldosterone receptor antagonists drug
dosing.
CLASS I
1. Aldosterone receptor antagonists (or mineralocorticoid
receptor antagonists) are recommended in patients with
NYHA class II–IV HF and who have LVEF of 35% or less,
unless contraindicated, to reduce morbidity and
mortality. Patients with NYHA class II HF should have
a history of prior cardiovascular hospitalization or
elevated plasma natriuretic peptide levels to be consid-
ered for aldosterone receptor antagonists. Creatinine
should be 2.5 mg/dL or less in men or 2.0 mg/dL or less
in women (or estimated glomerular ﬁltration rate >30
mL/min/1.73 m2), and potassium should be less than
5.0 mEq/L. Careful monitoring of potassium, renal
function, and diuretic dosing should be performed at
initiation and closely followed thereafter to minimize risk
of hyperkalemia and renal insufﬁciency (181,182,197).
(Level of Evidence: A)
2. Aldosterone receptor antagonists are recommended to
reduce morbidity and mortality following an acute MI in
patients who have LVEF of 40% or less who develop symp-
toms of HF or have a history of diabetes mellitus, unless
contraindicated (184). (Level of Evidence: B)
CLASS III: HARM
1. Inappropriate use of aldosterone receptor antagonists is
potentially harmful because of life-threatening hyperkalemia
or renal insufﬁciency when serum creatinine is greater than
Table 10. Oral Diuretics Recommended for Use in the
Treatment of Chronic HF
Drug Initial Daily Dose(s)
Maximum Total
Daily Dose
Duration
of Action
Loop diuretics
Bumetanide 0.5 to 1.0 mg
once or twice
10 mg 4 to 6 h
Furosemide 20 to 40 mg
once or twice
600 mg 6 to 8 h
Torsemide 10 to 20 mg once 200 mg 12 to 16 h
Thiazide diuretics
Chlorothiazide 250 to 500 mg
once or twice
1000 mg 6 to 12 h
Chlorthalidone 12.5 to 25.0 mg once 100 mg 24 to 72 h
Hydrochlorothiazide 25 mg once
or twice
200 mg 6 to 12 h
Indapamide 2.5 mg once 5 mg 36 h
Metolazone 2.5 mg once 20 mg 12 to 24 h
Potassium-sparing diuretics*
Amiloride 5 mg once 20 mg 24 h
Spironolactone 12.5 to 25.0 mg once 50 mgy 1 to 3 h
Triamterene 50 to 75 mg twice 200 mg 7 to 9 h
Sequential nephron blockade
Metolazonez 2.5 to 10.0 mg once
plus loop diuretic
N/A N/A
Hydrochlorothiazide 25 to 100 mg once
or twice plus loop
diuretic
N/A N/A
Chlorothiazide (IV) 500 to 1,000 mg
once plus loop
diuretic
N/A N/A
*Eplerenone, although also a diuretic, is primarily used in chronic HF.
yHigher doses may occasionally be used with close monitoring.
zSee Section 7.3.
HF indicates heart failure; IV, intravenous; and N/A, not applicable.
*In the absence of contraindications to anticoagulation.
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15082.5 mg/dL in men or greater than 2.0 mg/dL in women (or
estimated glomerular ﬁltration rate <30 mL/min/1.73 m2),
and/or potassium greater than 5.0 mEq/L (198,199). (Level
of Evidence: B)
6.3.2.6. HYDRALAZINE AND ISOSORBIDE DINITRATE
CLASS I
1. The combination of hydralazine and isosorbide dinitrate is
recommended to reduce morbidity and mortality for patients
self-described as African Americans with NYHA class III–IV
HFrEF receiving optimal therapy with ACE inhibitors and
beta blockers, unless contraindicated (179,180). (Level of
Evidence: A)
CLASS IIa
1. A combination of hydralazine and isosorbide dinitrate can be
useful to reduce morbidity or mortality in patients with
current or prior symptomatic HFrEF who cannot be given an
ACE inhibitor or ARB because of drug intolerance, hypoten-
sion, or renal insufﬁciency, unless contraindicated (188).
(Level of Evidence: B)See Table 13 for a summary of the treatment beneﬁt of
GDMT in HFrEF.6.3.2.7. DIGOXIN
CLASS IIa
1. Digoxin can be beneﬁcial in patients with HFrEF, unless
contraindicated, to decrease hospitalizations for HF
(202–209). (Level of Evidence: B)6.3.2.8. OTHER DRUG TREATMENT
6.3.2.8.1. Anticoagulation
CLASS I
1. Patients with chronic HF with permanent/persistent/
paroxysmal atrial ﬁbrillation (AF) and an additional
risk factor for cardioembolic stroke (history of hyper-
tension, diabetes mellitus, previous stroke or transient
ischemic attack, or ‡75 years of age) should receive
chronic anticoagulant therapy* (210–216). (Level of
Evidence: A)
2. The selection of an anticoagulant agent (warfarin, dabiga-
tran, apixaban, or rivaroxaban) for permanent/persistent/
paroxysmal AF should be individualized on the basis of
risk factors, cost, tolerability, patient preference, potential
for drug interactions, and other clinical characteristics,
including time in the international normalized ratio thera-
peutic range if the patient has been taking warfarin. (Level of
Evidence: C)
CLASS IIa
1. Chronic anticoagulation is reasonable for patients with
chronic HF who have permanent/persistent/paroxysmal AF
but are without an additional risk factor for cardioembolic
stroke* (211–213,217–219). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Anticoagulation is not recommended in patients with
chronic HFrEF without AF, a prior thromboembolic
event, or a cardioembolic source (220–222). (Level of
Evidence: B)
6.3.2.8.2. Statins
CLASS III: NO BENEFIT
1. Statins are not beneﬁcial as adjunctive therapy when
prescribed solely for the diagnosis of HF in the absence
of other indications for their use (223–228). (Level of
Evidence: A)6.3.2.8.3. Omega-3 Fatty Acids
CLASS IIa
1. Omega-3 polyunsaturated fatty acid supplementation is
reasonable to use as adjunctive therapy in patients with
NYHA class II–IV symptoms and HFrEF or HFpEF, unless
contraindicated, to reduce mortality and cardiovascular
hospitalizations (229,230). (Level of Evidence: B)
Table 11. Drugs Commonly Used for Stage C HFrEF
Drug Initial Daily Dose(s) Maximum Dose(s)
Mean Doses Achieved
in Clinical Trials
ACE inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times 122.7 mg/d (178)
Enalapril 2.5 mg twice 10 to 20 mg twice 16.6 mg/d (168)
Fosinopril 5 to 10 mg once 40 mg once N/A
Lisinopril 2.5 to 5 mg once 20 to 40 mg once 32.5 to 35.0 mg/d (183)
Perindopril 2 mg once 8 to 16 mg once N/A
Quinapril 5 mg twice 20 mg twice N/A
Ramipril 1.25 to 2.5 mg once 10 mg once N/A
Trandolapril 1 mg once 4 mg once N/A
ARBs
Candesartan 4 to 8 mg once 32 mg once 24 mg/d (176)
Losartan 25 to 50 mg once 50 to 150 mg once 129 mg/d (177)
Valsartan 20 to 40 mg twice 160 mg twice 254 mg/d (170)
Aldosterone antagonists
Spironolactone 12.5 to 25.0 mg once 25 mg once or twice 26 mg/d (181)
Eplerenone 25 mg once 50 mg once 42.6 mg/d (184)
Beta blockers
Bisoprolol 1.25 mg once 10 mg once 8.6 mg/d (185)
Carvedilol 3.125 mg twice 50 mg twice 37 mg/d (186)
Carvedilol CR 10 mg once 80 mg once N/A
Metoprolol succinate extended
release (metoprolol CR/XL)
12.5 to 25.0 mg once 200 mg once 159 mg/d (187)
Hydralazine and isosorbide dinitrate
Fixed-dose combination (180) 37.5 mg hydralazine/20 mg isosorbide
dinitrate 3 times daily
75 mg hydralazine/40 mg isosorbide
dinitrate 3 times daily
w175 mg hydralazine/90 mg
isosorbide dinitrate daily
Hydralazine and isosorbide
dinitrate (188)
Hydralazine: 25 to 50 mg, 3 or 4 times
daily and isosorbide dinitrate: 20 to
30 mg 3 or 4 times daily
Hydralazine: 300 mg daily in divided
doses and isosorbide dinitrate:
120 mg daily in divided doses
N/A
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CR, controlled release; CR/XL, controlled release/extended release; HFrEF, heart
failure with reduced ejection fraction; and N/A, not applicable.
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15096.3.2.9. DRUGS OF UNPROVEN VALUE OR THAT MAY
WORSEN HF
CLASS III: NO BENEFIT
1. Nutritional supplements as treatment for HF are not rec-
ommended in patients with current or prior symptoms of
HFrEF (231,232). (Level of Evidence: B)Table 12. Drug Dosing for Aldosterone Receptor Antagonists
Eplerenone
eGFR (mL/min/1.73 m2) 50 30 to 49
Initial dose (only if Kþ 5 mEq/L) 25 mg once daily 25 mg once ev
other day
Maintenance dose (after 4 wk
for Kþ 5 mEq/L)*
50 mg once daily 25 mg once d
*After dose initiation for Kþ, increase6.0 mEq/L, or worsening renal function,
resolution of hyperkalemia/renal insufficiency for at least 72 h.
eGFR indicates estimated glomerular filtration rate; and Kþ, potassium.
Adapted from Butler et al. (200).2. Hormonal therapies other than to correct deﬁciencies are
not recommended for patients with current or prior symp-
toms of HFrEF. (Level of Evidence: C)
CLASS III: HARM
1. Drugs known to adversely affect the clinical status of
patients with current or prior symptoms of HFrEF are
potentially harmful and should be avoided or withdrawnSpironolactone
50 30 to 49
ery 12.5 to 25.0 mg once daily 12.5 mg once daily or every
other day
aily 25 mg once or twice daily 12.5 to 25.0 mg once daily
hold until Kþ<5.0 mEq/L. Consider restarting reduced dose after confirming
Table 13. Medical Therapy for Stage C HFrEF:
Magnitude of Benefit Demonstrated in RCTs
GDMT
RR Reduction
in Mortality (%)
NNT for Mortality
Reduction
(Standardized
to 36 mo)
RR Reduction
in HF
Hospitalizations (%)
ACE inhibitor
or ARB
17 26 31
Beta blocker 34 9 41
Aldosterone
antagonist
30 6 35
Hydralazine/nitrate 43 7 33
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor
blocker; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF,
heart failure with reduced ejection fraction; NNT, number needed to treat;
RCTs, randomized controlled trials; and RR, relative risk.
Adapted with permission from Fonarow et al. (201).
yCounseling should be speciﬁc to each individual patient and should include
documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the
efﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-
brillation to be inactivated if desired in the future, notably when a patient is
approaching end of life. This will facilitate shared decision making between
patients, families, and the medical care team about ICDs (31).
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1510whenever possible (e.g., most antiarrhythmic drugs, most
calcium channel–blocking drugs [except amlodipine],
nonsteroidal anti-inﬂammatory drugs, or thiazolidinediones)
(233–244). (Level of Evidence: B)
2. Long-term use of infused positive inotropic drugs is poten-
tially harmful for patients with HFrEF, except as palliation for
patients with end-stage disease who cannot be stabilized
with standard medical treatment (see recommendations for
stage D). (Level of Evidence: C)
6.3.2.9.1. Calcium Channel Blockers
CLASS III: NO BENEFIT
1. Calcium channel–blocking drugs are not recommended as
routine treatment for patients with HFrEF (238,245,246).
(Level of Evidence: A)
See Table 14 for a summary of recommendations from this
section and Table 15 for strategies for achieving optimal
GDMT.
6.3.3. Pharmacological Treatment for Stage C HFpEF
See Table 16 for a summary of recommendations from this
section.
CLASS I
1. Systolic and diastolic blood pressure should be controlled in
patients with HFpEF in accordance with published clinical
practice guidelines to prevent morbidity (28,247). (Level of
Evidence: B)
2. Diuretics should be used for relief of symptoms due to volume
overload in patients with HFpEF. (Level of Evidence: C)
CLASS IIa
1. Coronary revascularization is reasonable in patients with
CAD in whom symptoms (angina) or demonstrable myo-
cardial ischemia is judged to be having an adverse effect on
symptomatic HFpEF despite GDMT. (Level of Evidence: C)
2. Management of AF according to published clinical practice
guidelines in patients with HFpEF is reasonable to improve
symptomatic HF. (Level of Evidence: C)
3. The use of beta-blocking agents, ACE inhibitors, and ARBs
in patients with hypertension is reasonable to control blood
pressure in patients with HFpEF. (Level of Evidence: C)CLASS IIb
1. The use of ARBs might be considered to decrease
hospitalizations for patients with HFpEF (248). (Level of
Evidence: B)
CLASS III: NO BENEFIT
1. Routine use of nutritional supplements is not recommended
for patients with HFpEF. (Level of Evidence: C)
6.3.4. Device Therapy for Stage C HFrEF
See Table 17 for a summary of recommendations from this
section.
CLASS I
1. ICD therapy is recommended for primary prevention of
sudden cardiac death to reduce total mortality in selected
patients with nonischemic dilated cardiomyopathy or
ischemic heart disease at least 40 days post-MI with
LVEF of 35% or less and NYHA class II or III symptoms on
chronic GDMT, who have reasonable expectation of mean-
ingful survival for more than 1 yeary (148,249). (Level of
Evidence: A)
2. Cardiac resynchronization therapy (CRT) is indicated for
patients who have LVEF of 35% or less, sinus rhythm, left
bundle-branch block (LBBB) with a QRS duration of 150 ms
or greater, and NYHA class II, III, or ambulatory IV symptoms
on GDMT. (Level of Evidence: A for NYHA class III/IV
(37,250–252); Level of Evidence: B for NYHA class II
(253,254).
3. ICD therapy is recommended for primary prevention of
sudden cardiac death to reduce total mortality in selected
patients at least 40 days post-MI with LVEF of 30% or less
and NYHA class I symptoms while receiving GDMT, who
have reasonable expectation of meaningful survival for more
than 1 yeary (255–257). (Level of Evidence: B)
CLASS IIa
1. CRT can be useful for patients who have LVEF of 35% or less,
sinus rhythm, a non-LBBB pattern with a QRS duration of
150 ms or greater, and NYHA class III/ambulatory class IV
symptoms on GDMT (250–252,254). (Level of Evidence: A)
2. CRT can be useful for patients who have LVEF of 35% or
less, sinus rhythm, LBBB with a QRS duration of 120 to 149
ms, and NYHA class II, III, or ambulatory IV symptoms on
GDMT (250–254,258). (Level of Evidence: B)
3. CRT can be useful in patients with AF and LVEF of 35% or less
on GDMT if a) the patient requires ventricular pacing or
otherwise meets CRT criteria and b) atrioventricular nodal
ablation or pharmacological rate control will allow near 100%
ventricular pacing with CRT (259–264). (Level of Evidence: B)
4. CRT can be useful for patients on GDMT who have LVEF
of 35% or less and are undergoing placement of a new or re-
placement device implantation with anticipated requirement
for signiﬁcant (>40%) ventricular pacing (261,265–267).
(Level of Evidence: C)
Table 14. Recommendations for Pharmacological Therapy for Management of Stage C HFrEF
Recommendations COR LOE References
Diuretics
Diuretics are recommended in patients with HFrEF with fluid retention I C N/A
ACE inhibitors
ACE inhibitors are recommended for all patients with HFrEF I A 134,167–169
ARBs
ARBs are recommended in patients with HFrEF who are ACE inhibitor intolerant I A 136,170,171,189
ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in HFrEF IIa A 190–195
Addition of an ARB may be considered in persistently symptomatic patients with
HFrEF on GDMT
IIb A 176,196
Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is
potentially harmful
III: Harm C N/A
Beta blockers
Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for
all stable patients
I A 137,172–175,187
Aldosterone receptor antagonists
Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV
who have LVEF 35%
I A 181,182,197
Aldosterone receptor antagonists are recommended in patients following an acute MI
who have LVEF 40% with symptoms of HF or DM
I B 184
Inappropriate use of aldosterone receptor antagonists may be harmful III: Harm B 198,199
Hydralazine and isosorbide dinitrate
The combination of hydralazine and isosorbide dinitrate is recommended for African
Americans with NYHA class III–IV HFrEF on GDMT
I A 179,180
A combination of hydralazine and isosorbide dinitrate can be useful in patients with
HFrEF who cannot be given ACE inhibitors or ARBs
IIa B 188
Digoxin
Digoxin can be beneficial in patients with HFrEF IIa B 202–209
Anticoagulation
Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional
risk factor for cardioembolic stroke should receive chronic anticoagulant therapy*
I A 210–216
The selection of an anticoagulant agent should be individualized I C N/A
Chronic anticoagulation is reasonable for patients with chronic HF who have permanent/
persistent/paroxysmal AF but are without an additional risk factor for cardioembolic
stroke*
IIa B 211–213,217–219
Anticoagulation is not recommended in patients with chronic HFrEF without AF,
a prior thromboembolic event, or a cardioembolic source
III: No Benefit B 220–222
Statins
Statins are not beneficial as adjunctive therapy when prescribed solely for HF III: No Benefit A 223–228
Omega-3 fatty acids
Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in HFrEF
or HFpEF patients
IIa B 229,230
Other drugs
Nutritional supplements as treatment for HF are not recommended in HFrEF III: No Benefit B 231,232
Hormonal therapies other than to correct deficiencies are not recommended in HFrEF III: No Benefit C N/A
Drugs known to adversely affect the clinical status of patients with HFrEF are
potentially harmful and should be avoided or withdrawn
III: Harm B 233–244
Long-term use of an infusion of a positive inotropic drug is not recommended
and may be harmful except as palliation
III: Harm C N/A
Calcium channel blockers
Calcium channel–blocking drugs are not recommended as routine treatment in HFrEF III: No Benefit A 238,245,246
*In the absence of contraindications to anticoagulation.
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; COR, Class of Recommendation; DM, diabetes mellitus;
GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not available; NYHA, New York Heart Association; and PUFA, poly-
unsaturated fatty acids.
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Table 15. Strategies for Achieving Optimal GDMT
1. Uptitrate in small increments to the recommended target dose or the highest tolerated dose for those medications listed in Table 11 with an appreciation that
some patients cannot tolerate the full recommended doses of all medications, particularly patients with low baseline heart rate or blood pressure or with a
tendency to postural symptoms.
2. Certain patients (e.g., the elderly, patients with chronic kidney disease) may require more frequent visits and laboratory monitoring during dose titration and
more gradual dose changes. However, such vulnerable patients may accrue considerable benefits from GDMT. Inability to tolerate optimal doses of GDMT
may change after disease-modifying interventions such as CRT.
3. Monitor vital signs closely before and during uptitration, including postural changes in blood pressure or heart rate, particularly in patients with orthostatic
symptoms, bradycardia, and/or “low” systolic blood pressure (e.g., 80 to 100 mmHg).
4. Alternate adjustments of different medication classes (especially ACE inhibitors/ARBs and beta blockers) listed in Table 11. Patients with elevated or normal
blood pressure and heart rate may tolerate faster incremental increases in dosages.
5. Monitor renal function and electrolytes for rising creatinine and hyperkalemia, recognizing that an initial rise in creatinine may be expected and does not
necessarily require discontinuation of therapy; discuss tolerable levels of creatinine above baseline with a nephrologist if necessary.
6. Patients may complain of symptoms of fatigue and weakness with dosage increases; in the absence of instability in vital signs, reassure them that these symptoms
are often transient and usually resolve within a few days of changes in therapy.
7. Discourage sudden spontaneous discontinuation of GDMT medications by the patient and/or other clinicians without discussion with managing clinicians.
8. Carefully review doses of other medications for HF symptom control (e.g., diuretics, nitrates) during uptitration.
9. Consider temporary adjustments in dosages of GDMT during acute episodes of noncardiac illnesses (e.g., respiratory infections, risk of dehydration, etc).
10. Educate patients, family members, and other clinicians about the expected benefits of achieving GDMT, including an understanding of the potential benefits of
myocardial reverse remodeling, increased survival, and improved functional status and HRQOL.
ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical
therapy; HF, heart failure; and HRQOL, health-related quality of life.
Table 16. Recommendations for Treatment of HFpEF
Recommendations COR LOE
Systolic and diastolic blood pressure should be controlled according to published clinical
practice guidelines
I B (28,247)
Diuretics should be used for relief of symptoms due to volume overload I C
Coronary revascularization for patients with CAD in whom angina or demonstrable
myocardial ischemia is present despite GDMT
IIa C
Management of AF according to published clinical practice guidelines for HFpEF to
improve symptomatic HF
IIa C
Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF IIa C
ARBs might be considered to decrease hospitalizations in HFpEF IIb B (248)
Nutritional supplementation is not recommended in HFpEF III: No Benefit C
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; COR,
Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction;
and LOE, Level of Evidence.
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1. The usefulness of implantation of an ICD is of uncertain
beneﬁt to prolong meaningful survival in patients with a high
risk of nonsudden death as predicted by frequent hospitali-
zations, advanced frailty, or comorbidities such as systemic
malignancy or severe renal dysfunctiony (268–271). (Level
of Evidence: B)
2. CRT may be considered for patients who have LVEF of 35%
or less, sinus rhythm, a non-LBBB pattern with a QRS
duration of 120 to 149 ms, and NYHA class III/ambulatory
class IV on GDMT (254,272). (Level of Evidence: B)yCounseling should be speciﬁc to each individual patient and should include
documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the
efﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-
brillation to be inactivated if desired in the future, notably when a patient is
approaching end of life. This will facilitate shared decision making between
patients, families, and the medical care team about ICDs (31).3. CRT may be considered for patients who have LVEF of 35%
or less, sinus rhythm, a non-LBBB pattern with a QRS
duration of 150 ms or greater, and NYHA class II symptoms
on GDMT (253,254). (Level of Evidence: B)
4. CRT may be considered for patients who have LVEF of
30% or less, ischemic etiology of HF, sinus rhythm, LBBB
with a QRS duration of 150 ms or greater, and NYHA class I
symptoms on GDMT (253,254). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. CRT is not recommended for patients with NYHA class I
or II symptoms and non-LBBB pattern with a QRS dura-
tion of less than 150 ms (253,254,272). (Level of
Evidence: B)
2. CRT is not indicated for patients whose comorbidities and/
or frailty limit survival with good functional capacity to less
than 1 year (37). (Level of Evidence: C)
See Figure 2, indications for CRT therapy algorithm.
Table 17. Recommendations for Device Therapy for Management of Stage C HF
Recommendations COR LOE References
ICD therapy is recommended for primary prevention of SCD in selected patients with HFrEF at least
40 d post-MI with LVEF 35% and NYHA class II or III symptoms on chronic GDMT,
who are expected to live >1 y*
I A 148,249
CRT is indicated for patients who have LVEF 35%, sinus rhythm, and LBBB with a QRS 150 ms,
and NYHA class II, III, or ambulatory IV symptoms on GDMT
I A
(NYHA class III/IV)
37,250–252
B
(NYHA class II)
253,254
ICD therapy is recommended for primary prevention of SCD in selected patients with HFrEF
at least 40 d post-MI with LVEF 30% and NYHA class I symptoms while receiving GDMT,
who are expected to live >1 y*
I B 255–257
CRT can be useful for patients who have LVEF 35%, sinus rhythm, a non-LBBB pattern with a
QRS 150 ms, and NYHA class III/ambulatory class IV symptoms on GDMT
IIa A 250–252,254
CRT can be useful for patients who have LVEF 35%, sinus rhythm, LBBB with a QRS 120 to 149 ms,
and NYHA class II, III, or ambulatory IV symptoms on GDMT
IIa B 250–254,258
CRT can be useful in patients with AF and LVEF 35% on GDMT if a) the patient requires ventricular
pacing or otherwise meets CRT criteria and b) AV nodal ablation or rate control allows near
100% ventricular pacing with CRT
IIa B 259–264
CRT can be useful for patients on GDMT who have LVEF 35% and are undergoing new or
replacement device implantation with anticipated ventricular pacing (>40%)
IIa C 261,265–267
An ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk of
nonsudden death such as frequent hospitalizations, frailty, or severe comorbidities*
IIb B 268–271
CRT may be considered for patients who have LVEF 35%, sinus rhythm, a non-LBBB pattern
with QRS 120 to 149 ms, and NYHA class III/ambulatory class IV on GDMT
IIb B 254,272
CRT may be considered for patients who have LVEF 35%, sinus rhythm, a non-LBBB pattern
with a QRS 150 ms, and NYHA class II symptoms on GDMT
IIb B 253,254
CRT may be considered for patients who have LVEF 30%, ischemic etiology of HF, sinus rhythm,
LBBB with QRS 150 ms, and NYHA class I symptoms on GDMT
IIb C 253,254
CRT is not recommended for patients with NYHA class I or II symptoms and a non-LBBB pattern
with QRS <150 ms
III: No Benefit B 253,254,272
CRT is not indicated for patients whose comorbidities and/or frailty limit survival to <1 y III: No Benefit C 37
*Counseling should be specific to each individual patient and should include documentation of a discussion about the potential for sudden death and nonsudden
death from HF or noncardiac conditions. Information should be provided about the efficacy, safety, and potential complications of an ICD and the potential for
defibrillation to be inactivated if desired in the future, notably when a patient is approaching end of life. This will facilitate shared decision making between patients,
families, and the medical care team about ICDs (31).
AF indicates atrial fibrillation; AV, atrioventricular; COR, Class of Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical
therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LBBB, left bundle-branch block; LOE,
Level of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; and SCD, sudden cardiac death.
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15136.4. Stage D
See Table 18 for the European Society of Cardiology
deﬁnition of advanced HF and Table 19 for clinical events
and ﬁndings useful for identifying patients with advanced HF.
6.4.1. Water Restriction
CLASS IIa
1. Fluid restriction (1.5 to 2 L/d) is reasonable in stage D,
especially in patients with hyponatremia, to reduce
congestive symptoms. (Level of Evidence: C)
6.4.2. Inotropic Support
See Table 20 for inotropic agents used in HF management and
Table 21 for a summary of recommendations from this section.
CLASS I
1. Until deﬁnitive therapy (e.g., coronary revascularization, MCS,
heart transplantation) or resolution of the acute precipitating
problem, patients with cardiogenic shock should receive tempo-
rary intravenous inotropic support to maintain systemic perfusion
and preserve end-organ performance. (Level of Evidence: C)CLASS IIa
1. Continuous intravenous inotropic support is reasonable as
“bridge therapy” in patients with stage D HF refractory to
GDMT and device therapy who are eligible for and awaiting
MCS or cardiac transplantation (275,276). (Level of
Evidence: B)
CLASS IIb
1. Short-term, continuous intravenous inotropic support may
be reasonable in those hospitalized patients presenting
with documented severe systolic dysfunction who present
with low blood pressure and signiﬁcantly depressed
cardiac output to maintain systemic perfusion and
preserve end-organ performance (277–279). (Level of
Evidence: B)
2. Long-term, continuous intravenous inotropic support
may be considered as palliative therapy for symptom
control in select patients with stage D HF despite
optimal GDMT and device therapy who are not eligible
for either MCS or cardiac transplantation (280–282).
(Level of Evidence: B)
Figure 2. Indications for CRT therapy algorithm. CRT indicates cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy-deﬁbrillator; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LBBB, left
bundle-branch block; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and NYHA, New York Heart Association.
Table 18. ESC Definition of Advanced HF
1. Severe symptoms of HF with dyspnea and/or fatigue at rest or with
minimal exertion (NYHA class III or IV)
2. Episodes of fluid retention (pulmonary and/or systemic congestion, peripheral
edema) and/or reduced cardiac output at rest (peripheral hypoperfusion)
3. Objective evidence of severe cardiac dysfunction shown by at least 1 of the
following:
a. LVEF <30%
b. Pseudonormal or restrictive mitral inflow pattern
c. Mean PCWP >16 mmHg and/or RAP >12 mmHg by PA catheterization
d. High BNP or NT-proBNP plasma levels in the absence of noncardiac causes
4. Severe impairment of functional capacity shown by 1 of the following:
a. Inability to exercise
b. 6-Minute walk distance 300 m
c. Peak _Vo2 <12 to 14 mL/kg/min
5. History of 1 HF hospitalization in past 6 mo
6. Presence of all the previous features despite “attempts to optimize” therapy,
including diuretics and GDMT, unless these are poorly tolerated or
contraindicated, and CRT when indicated
BNP indicates B-type natriuretic peptide; CRT, cardiac resynchronization
therapy; ESC, European Society of Cardiology; GDMT, guideline-directed
medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure;
and RAP, right atrial pressure.
Adapted from Metra et al. (33).
Table 19. Clinical Events and Findings Useful for Identifying
Patients With Advanced HF
Repeated (2) hospitalizations or ED visits for HF in the past year
Progressive deterioration in renal function (e.g., rise in BUN and creatinine)
Weight loss without other cause (e.g., cardiac cachexia)
Intolerance to ACE inhibitors due to hypotension and/or worsening renal
function
Intolerance to beta blockers due to worsening HF or hypotension
Frequent systolic blood pressure <90 mmHg
Persistent dyspnea with dressing or bathing requiring rest
Inability to walk 1 block on the level ground due to dyspnea or fatigue
Recent need to escalate diuretics to maintain volume status, often reaching
daily furosemide equivalent dose over 160 mg/d and/or use of supplemental
metolazone therapy
Progressive decline in serum sodium, usually to <133 mEq/L
Frequent ICD shocks
ACE indicates angiotensin-converting enzyme; BUN, blood urea nitrogen; ED,
emergency department; HF, heart failure; and ICD, implantable cardioverter-
defibrillator.
Adapted from Russell et al. (274).
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Table 20. Intravenous Inotropic Agents Used in Management of HF
Inotropic Agent
Dose (mcg/kg)
Drug Kinetics
and Metabolism
Effects
Adverse Effects Special ConsiderationsBolus Infusion (/min) CO HR SVR PVR
Adrenergic
agonists
Dopamine N/A 5 to 10 t1/2: 2 to 20 min
R,H,P
[ [ 4 4 T, HA, N, tissue
necrosis
Caution: MAO-I
N/A 10 to 15 [ [ [ 4
Dobutamine N/A 2.5 to 5 t1/2: 2 to 3 min
H
[ [ Y 4 [/YBP, HA, T, N, F,
hypersensitivity
Caution: MAO-I;
CI: sulfite allergyN/A 5 to 20 [ [ 4 4
PDE inhibitor
Milrinone N/R 0.125 to 0.75 t1/2: 2.5 h H [ [ Y Y T, YBP Renal dosing,
monitor LFTs
BP indicates blood pressure; CI, contraindication; CO, cardiac output; F, fever; H, hepatic; HA, headache; HF, heart failure; HR, heart rate; LFT, liver function test;
MAO-I, monoamine oxidase inhibitor; N, nausea; N/A, not applicable; N/R, not recommended; P, plasma; PDE, phosphodiesterase; PVR, pulmonary vascular resistance;
R, renal; SVR, systemic vascular resistance; T, tachyarrhythmias; and t1/2, elimination half-life.
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1515CLASS III: HARM
1. Long-term use of either continuous or intermittent, intrave-
nous parenteral positive inotropic agents, in the absence of
speciﬁc indications or for reasons other than palliative care,
is potentially harmful in the patient with HF (172,283–288).
(Level of Evidence: B)Table 21. Recommendations for Inotropic Support, MCS, and Car
Recommendations
Inotropic support
Cardiogenic shock pending definitive therapy or resolution
BTT or MCS in stage D refractory to GDMT
Short-term support for threatened end-organ dysfunction in hospitalized pati
with stage D and severe HFrEF
Long-term support with continuous infusion palliative therapy in select stage
Routine intravenous use, either continuous or intermittent, is potentially harm
in stage D HF
Short-term intravenous use in hospitalized patients without evidence of shoc
threatened end-organ performance is potentially harmful
MCS
MCS is beneficial in carefully selected* patients with stage D HF in whom d
management (e.g., cardiac transplantation) is anticipated or planned
Nondurable MCS is reasonable as a “bridge to recovery” or a “bridge to dec
for carefully selected* patients with HF and acute profound disease
Durable MCS is reasonable to prolong survival for carefully selected* patient
stage D HFrEF
Cardiac transplantation
Evaluation for cardiac transplantation is indicated for carefully selected patie
with stage D HF despite GDMT, device, and surgical management
*Although optimal patient selection for MCS remains an active area of inves
patients with LVEF <25% and NYHA class III–IV functional status despite GDMT,
year mortality (e.g., as suggested by markedly reduced peak oxygen consumpt
parenteral inotropic support. Patient selection requires a multidisciplinary team
cardiothoracic surgeons, nurses, and ideally, social workers and palliative care
BTT indicates bridge to transplant; COR, Class of Recommendation; CRT, card
therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LO
mechanical circulatory support; N/A, not applicable; and NYHA, New York Hear2. Use of parenteral inotropic agents in hospitalized patients
without documented severe systolic dysfunction, low
blood pressure, or impaired perfusion and evidence of
signiﬁcantly depressed cardiac output, with or without
congestion, is potentially harmful (277–279). (Level of
Evidence: B)diac Transplantation
COR LOE References
I C N/A
IIa B 275,276
ents IIb B 277–279
D HF IIb B 280–282
ful III: Harm B 172,283–288
k or III: Harm B 277–279
efinitive IIa B 289–296
ision” IIa B 297–300
s with IIa B 301–304
nts I C 305
tigation, general indications for referral for MCS therapy include
including, when indicated, CRT, with either high predicted 1- to 2-
ion and clinical prognostic scores) or dependence on continuous
of experienced advanced HF and transplantation cardiologists,
clinicians.
iac resynchronization therapy; GDMT, guideline-directed medical
E, Level of Evidence; LVEF, left ventricular ejection fraction; MCS,
t Association.
Figure 3. Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
AF, atrial ﬁbrillation; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; DM, diabetes
mellitus; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; HRQOL, health-related quality of life; HTN, hypertension; ICD, implantable
cardioverter-deﬁbrillator; LV, left ventricular; LVH, left ventricular hypertrophy; MCS, mechanical circulatory support; and MI, myocardial
infarction. Adapted from Hunt et al (37).
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15166.4.3. Mechanical Circulatory Support
CLASS IIa
1. MCS is beneﬁcial in carefully selectedz patients with stage
D HFrEF in whom deﬁnitive management (e.g., cardiac
transplantation) or cardiac recovery is anticipated or
planned (289–296). (Level of Evidence: B)
2. Nondurable MCS, including the use of percutaneous
and extracorporeal ventricular assist devices, is reasonable
as a “bridge to recovery” or a “bridge to decision” for carefully
selectedz patients with HFrEF with acute, profound hemody-
namic compromise (297–300). (Level of Evidence: B)zAlthough optimal patient selection for MCS remains an active area of investiga-
tion, general indications for referral for MCS therapy include patients with
LVEF <25% and NYHA class III–IV functional status despite GDMT, including,
when indicated, CRT, with either high predicted 1- to 2-year mortality (e.g., as
suggested by markedly reduced peak oxygen consumption and clinical prognostic
scores) or dependence on continuous parenteral inotropic support. Patient selection
requires a multidisciplinary team of experienced advanced HF and transplantation
cardiologists, cardiothoracic surgeons, nurses, and ideally, social workers and
palliative care clinicians.3. Durable MCS is reasonable to prolong survival for carefully
selectedz patients with stage D HFrEF (301–304). (Level of
Evidence: B)6.4.4. Cardiac Transplantation
CLASS I
1. Evaluation for cardiac transplantation is indicated for carefully
selected patients with stage D HF despite GDMT, device, and
surgical management (305). (Level of Evidence: C)
See Figure 3 for the stages in the development of HF.7. The Hospitalized Patient:
Recommendations
See Table 22 for a summary of recommendations from this
section and Figure 4 for the classiﬁcation of patients
presenting with acutely decompensated HF.
Table 22. Recommendations for Therapies in the Hospitalized HF Patient
Recommendations COR LOE References
HF patients hospitalized with fluid overload should be treated with intravenous diuretics I B 310,311
HF patients receiving loop diuretic therapy should receive an initial parenteral dose greater
than or equal to their chronic oral daily dose; then dose should be serially adjusted
I B 312
HFrEF patients requiring HF hospitalization on GDMT should continue GDMT except in cases
of hemodynamic instability or where contraindicated
I B 307–309
Initiation of beta-blocker therapy at a low dose is recommended after optimization of volume
status and discontinuation of intravenous agents
I B 307–309
Thrombosis/thromboembolism prophylaxis is recommended for patients hospitalized with HF I B 22,324–328
Serum electrolytes, urea nitrogen, and creatinine should be measured during titration of
HF medications, including diuretics
I C N/A
When diuresis is inadequate, it is reasonable to IIa
B 37,312a. give higher doses of intravenous loop diuretics; or
b. add a second diuretic (e.g., thiazide) B 313–316
Low-dose dopamine infusion may be considered with loop diuretics to improve diuresis IIb B 317,318
Ultrafiltration may be considered for patients with obvious volume overload IIb B 319
Ultrafiltration may be considered for patients with refractory congestion IIb C N/A
Intravenous nitroglycerin, nitroprusside, or nesiritide may be considered an adjuvant to
diuretic therapy for stable patients with HF
IIb A 320–323
In patients hospitalized with volume overload and severe hyponatremia, vasopressin
antagonists may be considered
IIb B 330,331
COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced
ejection fraction; LOE, Level of Evidence; and N/A, not available.
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15177.1. Precipitating Causes of
Decompensated HF
CLASS I
1. ACS precipitating acute HF decompensation should be
promptly identiﬁed by electrocardiogram and serum
biomarkers, including cardiac troponin testing, and treated
optimally as appropriate to the overall condition and prog-
nosis of the patient. (Level of Evidence: C)
2. Common precipitating factors for acute HF should be
considered during initial evaluation, as recognition of these
conditions is critical to guide appropriate therapy. (Level of
Evidence: C)No
No Warm and Dry
Cold and Dry
Yes
Yes
Warm and Wet
Cold and Wet
Congestion at rest?
(e.g. orthopnea, elevated jugular venous pressure,
pulmonary rales, S3 gallop, edema)
(
e
.
g
.
 
n
a
r
r
o
w
 
p
u
l
s
e
 
p
r
e
s
s
u
r
e
,
c
o
o
l
 
e
x
t
r
e
m
i
t
i
e
s
,
 
h
y
p
o
t
e
n
s
i
o
n
)
L
o
w
 
p
e
r
f
u
s
i
o
n
 
a
t
 
r
e
s
t
?
Figure 4. Classiﬁcation of patients presenting with acutely
decompensated heart failure. Adapted with permission from
Nohria et al. (306).7.2. Maintenance of GDMT During
Hospitalization
CLASS I
1. In patients with HFrEF experiencing a symptomatic exac-
erbation of HF requiring hospitalization during chronic
maintenance treatment with GDMT, it is recommended that
GDMT be continued in the absence of hemodynamic insta-
bility or contraindications (307–309). (Level of Evidence: B)
2. Initiation of beta-blocker therapy is recommended after
optimization of volume status and successful discontinua-
tion of intravenous diuretics, vasodilators, and inotropic
agents. Beta-blocker therapy should be initiated at a low
dose and only in stable patients. Caution should be used
when initiating beta blockers in patients who have required
inotropes during their hospital course (307–309). (Level of
Evidence: B)
7.3. Diuretics in Hospitalized Patients
CLASS I
1. Patients with HF admitted with evidence of signiﬁcant
ﬂuid overload should be promptly treated with intravenous
loop diuretics to reduce morbidity (310,311). (Level of
Evidence: B)
2. If patients are already receiving loop diuretic therapy, the
initial intravenous dose should equal or exceed their chronic
oral daily dose and should be given as either intermittent
boluses or continuous infusion. Urine output and signs and
symptoms of congestion should be serially assessed, and
the diuretic dose should be adjusted accordingly to relieve
symptoms, reduce volume excess, and avoid hypotension
(312). (Level of Evidence: B)
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15183. The effect of HF treatment should be monitored with
careful measurement of ﬂuid intake and output, vital signs,
body weight that is determined at the same time each day,
and clinical signs and symptoms of systemic perfusion and
congestion. Daily serum electrolytes, urea nitrogen, and
creatinine concentrations should be measured during the
use of intravenous diuretics or active titration of HF medi-
cations. (Level of Evidence: C)
CLASS IIa
1. When diuresis is inadequate to relieve symptoms, it is
reasonable to intensify the diuretic regimen using either:a. higher doses of intravenous loop diuretics (37,312)
(Level of Evidence: B);
b. addition of a second (e.g., thiazide) diuretic (313–316).
(Level of Evidence: B)CLASS IIb
1. Low-dose dopamine infusion may be considered in addition
to loop diuretic therapy to improve diuresis and better
preserve renal function and renal blood ﬂow (317,318).
(Level of Evidence: B)
7.4. Renal Replacement Therapyd
Ultraﬁltration
CLASS IIb
1. Ultraﬁltration may be considered for patients with obvious
volume overload to alleviate congestive symptoms and ﬂuid
weight (319). (Level of Evidence: B)
2. Ultraﬁltration may be considered for patients with refractory
congestion not responding to medical therapy. (Level of
Evidence: C)
7.5. Parenteral Therapy in Hospitalized HF
CLASS IIb
1. If symptomatic hypotension is absent, intravenous nitro-
glycerin, nitroprusside, or nesiritide may be considered anTable 23. Recommendations for Hospital Discharge
Recommendations or Indications
Performance improvement systems in the hospital and early postdischarge o
to identify HF for GDMT
Before hospital discharge, at the first postdischarge visit, and in subsequent
the following should be addressed:
a. initiation of GDMT if not done or contraindicated;
b. causes of HF, barriers to care, and limitations in support;
c. assessment of volume status and blood pressure with
adjustment of HF therapy;
d. optimization of chronic oral HF therapy;
e. renal function and electrolytes;
f. management of comorbid conditions;
g. HF education, self-care, emergency plans, and adherence; and
h. palliative or hospice care
Multidisciplinary HF disease management for patients at high risk for hospita
A follow-up visit within 7 to 14 d and a telephone follow-up within 3 d of ho
are reasonable
Use of clinical risk-prediction tools and/or biomarkers to identify higher-risk
are reasonable
OR indicates Class of Recommendation; GDMT, guideline-directed medicaadjuvant to diuretic therapy for relief of dyspnea in patients
admitted with acutely decompensated HF (320–323). (Level
of Evidence: A)
7.6. Venous Thromboembolism Prophylaxis
in Hospitalized Patients
CLASS I
1. A patient admitted to the hospital with decompensated HF
should receive venous thromboembolism prophylaxis with
an anticoagulant medication if the riskLbeneﬁt ratio is
favorable (22,324–328). (Level of Evidence: B)
7.7. Arginine Vasopressin Antagonists
CLASS IIb
1. In patients hospitalized with volume overload, including
HF, who have persistent severe hyponatremia and are at
risk for or having active cognitive symptoms despite
water restriction and maximization of GDMT, vasopressin
antagonists may be considered in the short term to improve
serum sodium concentration in hypervolemic, hypona-
tremic states with either a V2 receptor selective or
a nonselective vasopressin antagonist (330,331). (Level of
Evidence: B)
7.8. Inpatient and Transitions of Care
See Table 23 for a summary of recommendations from this
section.
CLASS I
1. The use of performance improvement systems and/or
evidence-based systems of care is recommended in the
hospital and early postdischarge outpatient setting to
identify appropriate HF patients for GDMT, provide clinicians
with useful reminders to advance GDMT, and assess the
clinical response (151,332–338). (Level of Evidence: B)
2. Throughout the hospitalization as appropriate, before
hospital discharge, at the ﬁrst postdischarge visit, and inCOR LOE References
utpatient setting I B 151,332–338
follow-up visits, I B 57,337,339–341
l readmission I B 336,342–344
spital discharge IIa B 345,346
patients IIa B 62
l therapy; HF, heart failure; and LOE, Level of Evidence.
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1519subsequent follow-up visits, the following should be
addressed (57,337,339–341). (Level of Evidence: B):
a. initiation of GDMT if not previously established and not
contraindicated;
b. precipitant causes of HF, barriers to optimal care tran-
sitions, and limitations in postdischarge support;
c. assessment of volume status and supine/upright hypo-
tension with adjustment of HF therapy as appropriate;
d. titration and optimization of chronic oral HF therapy;
e. assessment of renal function and electrolytes where
appropriate;
f. assessment and management of comorbid conditions;
g. reinforcement of HF education, self-care, emergency
plans, and need for adherence; and
h. consideration for palliative care or hospice care in
selected patients.
3. Multidisciplinary HF disease-management programs are
recommended for patients at high risk for hospital read-
mission, to facilitate the implementation of GDMT, to
address different barriers to behavioral change, and to
reduce the risk of subsequent rehospitalization for HF
(336,342–344). (Level of Evidence: B)
CLASS IIa
1. Scheduling an early follow-up visit (within 7 to 14
days) and early telephone follow-up (within 3 days) of hospital
discharge are reasonable (345,346). (Level of Evidence: B)
2. Use of clinical risk-prediction tools and/or biomarkers
to identify patients at higher risk for postdischarge clinical
events are reasonable (62). (Level of Evidence: B)8. Important Comorbidities in HF
Although there are additional and important comorbidities that
occur in patients with HF as referenced in Table 24, it remains
uncertain how best to generate speciﬁc recommendations,
given the status of current evidence.Table 24. Ten Most Common Co-Occurring Chronic Conditions Among M
Beneficiaries Age 65 y (N¼4,376,150)*
N %
Hypertension 3,685,373 84
Ischemic heart disease 3,145,718 71
Hyperlipidemia 2,623,601 60
Anemia 2,200,674 50
Diabetes 2,027,875 46
Arthritis 1,901,447 43
Chronic kidney disease 1,851,812 42
COPD 1,311,118 30
Atrial fibrillation 1,247,748 28
Alzheimer’s disease/dementia 1,207,704 27
*Mean No. of conditions is 6.1; median is 6.
yMean No. of conditions is 5.5; median is 5.
COPD indicates chronic obstructive pulmonary disease.
Data source: Centers for Medicare and Medicaid Services administrative claims data
ccwdata.org (347).9. Surgical/Percutaneous/Transcatheter
Interventional Treatments of HF:
Recommendations
See Table 25 for a summary of recommendations from this
section.
CLASS I
1. Coronary artery revascularization via coronary artery bypass
graft surgery (CABG) or percutaneous intervention is
indicated for patients (HFpEF and HFrEF) on GDMT
with angina and suitable coronary anatomy, especially for
a left main stenosis (>50%) or left main equivalent disease
(11,13,15,348). (Level of Evidence: C)
CLASS IIa
1. CABG to improve survival is reasonable in patients with
mild to moderate LV systolic dysfunction (EF 35% to 50%)
and signiﬁcant (‡70% diameter stenosis) multivessel CAD or
proximal left anterior descending coronary artery stenosis
when viable myocardium is present in the region of intended
revascularization (348–350). (Level of Evidence: B)
2. CABG or medical therapy is reasonable to improve morbidity
and cardiovascular mortality for patients with severe LV
dysfunction (EF <35%), HF, and signiﬁcant CAD (351,352).
(Level of Evidence: B)
3. Surgical aortic valve replacement is reasonable for
patients with critical aortic stenosis and a predicted surgical
mortality of no greater than 10% (353). (Level of Evidence: B)
4. Transcatheter aortic valve replacement after careful candi-
date consideration is reasonable for patients with critical
aortic stenosis who are deemed inoperable (354). (Level of
Evidence: B)
CLASS IIb
1. CABG may be considered with the intent of improving
survival in patients with ischemic heart disease with
severe LV systolic dysfunction (EF <35%) and operable
coronary anatomy whether or not viable myocardium is
present (352,355,356). (Level of Evidence: B)edicare Beneficiaries With Heart Failure (N[4,947,918), 2011
Beneficiaries Age <65 y (N¼5,71,768)y
N %
.2 Hypertension 461,235 80.7
.9 Ischemic heart disease 365,889 64.0
.0 Diabetes 338,687 59.2
.3 Hyperlipidemia 325,498 56.9
.3 Anemia 284,102 49.7
.5 Chronic kidney disease 257,015 45.0
.3 Depression 207,082 36.2
.0 Arthritis 201,964 35.3
.5 COPD 191,016 33.4
.6 Asthma 888,16 15.5
, January 2011December 2011, from the Chronic Condition Warehouse (CCW),
Table 25. Recommendations for Surgical/Percutaneous/Transcatheter Interventional Treatments of HF
Recommendations COR LOE References
CABG or percutaneous intervention is indicated for HF patients on GDMT with angina and suitable
coronary anatomy, especially significant left main stenosis or left main equivalent
I C 11,13,15,348
CABG to improve survival is reasonable in patients with mild to moderate LV systolic dysfunction and
significant multivessel CAD or proximal LAD stenosis when viable myocardium is present
IIa B 348–350
CABG or medical therapy is reasonable to improve morbidity and mortality for patients with severe
LV dysfunction (EF <35%), HF, and significant CAD
IIa B 351,352
Surgical aortic valve replacement is reasonable for patients with critical aortic stenosis
and a predicted surgical mortality of no greater than 10%
IIa B 353
Transcatheter aortic valve replacement is reasonable for patients with critical aortic stenosis
who are deemed inoperable
IIa B 354
CABG may be considered in patients with ischemic heart disease, severe LV systolic dysfunction,
and operable coronary anatomy whether or not viable myocardium is present
IIb B 352,355,356
Transcatheter mitral valve repair or mitral valve surgery for functional mitral insufficiency is of
uncertain benefit
IIb B 357–360
Surgical reverse remodeling or LV aneurysmectomy may be considered in HFrEF for specific
indications, including intractable HF and ventricular arrhythmias
IIb B 361
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, Class of Recommendation; EF, ejection fraction; GDMT, guideline-directed medical
therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LAD, left anterior descending; LOE, Level of Evidence; and LV, left ventricular.
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15202. Transcatheter mitral valve repair or mitral valve surgery for
functional mitral insufﬁciency is of uncertain beneﬁt and
should only be considered after careful candidate selection and
with a background of GDMT (357–360). (Level of Evidence: B)
3. Surgical reverse remodeling or LV aneurysmectomy may be
considered in carefully selected patients with HFrEF for
speciﬁc indications, including intractable HF and ventricular
arrhythmias (361). (Level of Evidence: B)
10. Coordinating Care for Patients With
Chronic HF: Recommendations
CLASS I
1. Effective systems of care coordination with special atten-
tion to care transitions should be deployed for every patient
with chronic HF that facilitate and ensure effective care that
is designed to achieve GDMT and prevent hospitalization
(333,336,362–377). (Level of Evidence: B)
2. Every patient with HF should have a clear, detailed, and
evidence-based plan of care that ensures the achievement
of GDMT goals, effective management of comorbid condi-
tions, timely follow-up with the healthcare team, appropriate
dietary and physical activities, and compliance with
secondary prevention guidelines for cardiovascular disease.
This plan of care should be updated regularly and made
readily available to all members of each patient’s healthcare
team (14). (Level of Evidence: C)
3. Palliative and supportive care is effective for patients
with symptomatic advanced HF to improve quality of life
(31,378–381). (Level of Evidence: B)
11. QualityMetrics/PerformanceMeasures:
Recommendations
CLASS I
1. Performance measures based on professionally developed
clinical practice guidelines should be used with the goal of
improving quality of care for HF (334,343,382). (Level of
Evidence: B)CLASS IIa
1. Participation in quality improvement programs and patient
registries based on nationally endorsed, clinical practice
guidelineLbased quality and performance measures can
be beneﬁcial in improving quality of HF care (334,343).
(Level of Evidence: B)
See Table 26 for a revised ACCF/AHA/PCPI 2011 HF
measurement set.
12. Evidence Gaps and Future
Research Directions
Despite the objective evidence compiled by the writing
committee on the basis of hundreds of clinical trials, there are
huge gaps in our knowledge base about many fundamental
aspects of HF care. Some key examples include an effective
management strategy for patients with HFpEF beyond blood
pressure control; a convincing method to use biomarkers in the
optimizationofmedical therapy; the recognition and treatment of
cardiorenal syndrome; and the critical need for improving patient
adherence to therapeutic regimens. Even the widely embraced
dictum of sodium restriction in HF is not well supported by
current evidence.Moreover, themajority of the clinical trials that
inform GDMT were designed around the primary endpoint of
mortality, so that there is less certainty about the impact of
therapies on the health-related quality of life of patients. It is also
ofmajor concern that themajority of randomized controlled trials
failed to randomize a sufﬁcient number of the elderly, women,
and underrepresented minorities, thus limiting our insight into
these important patient cohorts. A growing body of studies on
patient-centered outcomes research is likely to address some of
these deﬁciencies, but time will be required.
HF is a syndrome with a high prevalence of comorbidities
and multiple chronic conditions, but most guidelines are
developed for patients with a single disease. Nevertheless,
the coexistence of additional diseases such as arthritis, renal
Table 26. ACCF/AHA/AMA-PCPI 2011 HF Measurement Set
Measure Description* Care Setting Level of Measurement
1. LVEF assessment Percentage of patients aged 18 y with a diagnosis of HF for
whom the quantitative or qualitative results of a recent
or prior (any time in the past) LVEF assessment is
documented within a 12-mo period
Outpatient Individual practitioner
2. LVEF assessment Percentage of patients aged 18 y with a principal discharge
diagnosis of HF with documentation in the hospital record
of the results of an LVEF assessment performed either
before arrival or during hospitalization, OR documentation
in the hospital record that LVEF assessment is planned
for after discharge
Inpatient  Individual practitioner
 Facility
3. Symptom and activity assessment Percentage of patient visits for patients aged 18 y with a
diagnosis of HF with quantitative results of an evaluation
of both current level of activity and clinical symptoms
documented
Outpatient Individual practitioner
4. Symptom managementy Percentage of patient visits for patients aged 18 y with a diagnosis
of HF and with quantitative results of an evaluation of both level of
activity AND clinical symptoms documented in which patient
symptoms have improved or remained consistent with treatment
goals since last assessment OR patient symptoms have
demonstrated clinically important deterioration since last
assessment with a documented plan of care
Outpatient Individual practitioner
5. Patient self-care educationyz Percentage of patients aged 18 y with a diagnosis of HF
who were provided with self-care education on 3 elements
of education during 1 visits within a 12-mo period
Outpatient Individual practitioner
6. Beta-blocker therapy for LVSD
(outpatient and inpatient setting)
Percentage of patients aged 18 y with a diagnosis of HF with a
current or prior LVEF <40% who were prescribed beta-blocker
therapy with bisoprolol, carvedilol, or sustained-release
metoprolol succinate either within a 12-mo period when
seen in the outpatient setting or at hospital discharge
Inpatient and
outpatient
 Individual practitioner
 Facility
7. ACE inhibitor or ARB therapy
for LVSD (outpatient and
inpatient setting)
Percentage of patients aged 18 y with a diagnosis of HF with a
current or prior LVEF <40% who were prescribed ACE inhibitor
or ARB therapy either within a 12-mo period when seen in the
outpatient setting or at hospital discharge
Inpatient and
outpatient
 Individual practitioner
 Facility
8. Counseling about ICD implantation
for patients with LVSD on
combination medical therapyyz
Percentage of patients aged 18 y with a diagnosis of HF with
current LVEF 35% despite ACE inhibitor/ARB and beta-blocker
therapy for at least 3 mo who were counseled about ICD
placement as a treatment option for the prophylaxis
of sudden death
Outpatient Individual practitioner
9. Postdischarge appointment for
HF patients
Percentage of patients, regardless of age, discharged from an
inpatient facility to ambulatory care or home health care
with a principal discharge diagnosis of HF for whom a
follow-up appointment was scheduled and documented,
including location, date, and time for a follow-up office
visit or home health visit (as specified)
Inpatient Facility
N.B., Regarding test measure no. 8, implantation of an ICD must be consistent with published guidelines. This measure is intended to promote counseling only.
*Refer to the complete measures for comprehensive information, including measure exception.
yTest measure designated for use in internal quality improvement programs only. These measures are not appropriate for any other purpose (e.g., pay for
performance, physician ranking, or public reporting programs).
zNew measure.
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-converting enzyme; AHA, American Heart Association; AMA-PCPI, American Medical
AssociationPhysician Consortium for Performance Improvement; ARB, angiotensin-receptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;
LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.
Adapted from Bonow et al. (383).
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1521insufﬁciency, diabetes mellitus, or chronic lung disease with
the HF syndrome should logically require a modiﬁcation of
treatment, outcome assessment, or follow-up care. About 25%
of Americans have multiple chronic conditions; this ﬁgurerises to 75% in those >65 years of age, including the diseases
referred to above, as well as asthma, hypertension, cognitive
disorders, or depression (347). Most randomized controlled
trials in HF speciﬁcally excluded patients with signiﬁcant
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1522other comorbidities from enrollment, thus limiting our ability to
generalize our recommendations to many real-world patients.
Therefore, the clinician must, as always, practice the art of
using the best of the guideline recommendations as they
apply to a speciﬁc patient.
Future research will need to focus on novel pharmacolog-
ical therapies, especially for patients hospitalized with HF;
regenerative cell-based therapies to restore myocardium; and
new device platforms that will either improve existing tech-
nologies (e.g., CRT, ICD, left ventricular assist device) or
introduce simpler, less morbid devices that are capable of
changing the natural history of HF. What is critically needed
is an evidence base that clearly identiﬁes best processes of
care, especially in the transition from hospital to home.
Finally, preventing the burden of this disease through more
successful risk modiﬁcation, sophisticated screening, perhaps
using speciﬁc omics technologies (i.e., systems biology), or
effective treatment interventions that reduce the progression
from stage A to stage B is an urgent need.
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